$ENDV
ENDONOVO THERAPEUTICS, INC.

2023 Q3 Form 10-Q Financial Statement

#000149315223029706 Filed on August 21, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $1.520K $45.20K
YoY Change -86.13% 6853.85%
Cost Of Revenue $827.00
YoY Change -79.46%
Gross Profit $693.00 $45.20K
YoY Change -90.0% 16828.84%
Gross Profit Margin 45.59% 100.0%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $161.7K $161.7K
YoY Change 0.01% 0.0%
% of Gross Profit 23337.66% 357.81%
Operating Expenses $473.5K $1.177M
YoY Change -6.0% -34.6%
Operating Profit -$472.8K -$1.131M
YoY Change -4.83% -37.11%
Interest Expense -$285.9K $3.107M
YoY Change -27.58% -574.92%
% of Operating Profit
Other Income/Expense, Net -$293.4K $3.195M
YoY Change 175.26% -539.24%
Pretax Income -$766.2K $2.064M
YoY Change 26.98% -181.69%
Income Tax
% Of Pretax Income
Net Earnings -$766.2K $2.064M
YoY Change 26.98% -181.69%
Net Earnings / Revenue -50405.92% 4565.62%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 -$0.01
COMMON SHARES
Basic Shares Outstanding 317.9M shares 270.3M shares
Diluted Shares Outstanding 1.351B shares 1.351B shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $32.60K
YoY Change -100.0%
Cash & Equivalents $0.00 $32.60K
Short-Term Investments
Other Short-Term Assets $35.50K $40.23K
YoY Change 704.6%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $35.50K $72.83K
YoY Change 47.42% 1125.11%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $780.3K $942.0K
YoY Change -45.33% -40.71%
TOTAL ASSETS
Total Short-Term Assets $35.50K $72.83K
Total Long-Term Assets $780.3K $942.0K
Total Assets $815.8K $1.015M
YoY Change -43.79% -36.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.460M $1.449M
YoY Change 68.6% 84.34%
Accrued Expenses $9.277M $8.758M
YoY Change 21.49% 20.91%
Deferred Revenue
YoY Change
Short-Term Debt $7.057M $7.027M
YoY Change -2.53% -4.48%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $23.70M $23.14M
YoY Change 12.96% 11.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $79.83K $79.83K
YoY Change 0.0% 0.0%
Total Long-Term Liabilities $79.83K $79.83K
YoY Change 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.70M $23.14M
Total Long-Term Liabilities $79.83K $79.83K
Total Liabilities $23.78M $23.22M
YoY Change 12.91% 11.86%
SHAREHOLDERS EQUITY
Retained Earnings -$66.60M -$65.90M
YoY Change 7.42% 7.33%
Common Stock $27.94K $27.88K
YoY Change 75.48% 85.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$22.96M -$22.20M
YoY Change
Total Liabilities & Shareholders Equity $815.8K $1.015M
YoY Change -43.79% -36.37%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$766.2K $2.064M
YoY Change 26.98% -181.69%
Depreciation, Depletion And Amortization $161.7K $161.7K
YoY Change 0.01% 0.0%
Cash From Operating Activities -$65.36K -$165.8K
YoY Change -47.23% -19.69%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 32.77K 187.5K
YoY Change -77.71% 27.99%
NET CHANGE
Cash From Operating Activities -65.36K -165.8K
Cash From Investing Activities
Cash From Financing Activities 32.77K 187.5K
Net Change In Cash -32.59K 21.66K
YoY Change -240.84% -136.11%
FREE CASH FLOW
Cash From Operating Activities -$65.36K -$165.8K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91367
dei Entity Central Index Key
EntityCentralIndexKey
0001528172
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
ENDV Conversion Of Preferred C Stock To Common Stock
ConversionOfPreferredCStockToCommonStock
usd
ENDV Issuance Of Common Stock To Settle Debt
IssuanceOfCommonStockToSettleDebt
usd
ENDV Conversion Of Notes To Common Stock Pursuant To Settlement Agreement
ConversionOfNotesToCommonStockPursuantToSettlementAgreement
usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
usd
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
shares
CY2022Q2 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
usd
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-55453
dei Entity Registrant Name
EntityRegistrantName
ENDONOVO THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-2552528
dei Entity Address Address Line1
EntityAddressAddressLine1
6320 Canoga Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
15th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Woodland Hills
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei City Area Code
CityAreaCode
(800)
dei Local Phone Number
LocalPhoneNumber
489-4774
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
317902405 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32602 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
40231 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
15724 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
72833 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
15822 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
941988 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1265444 usd
CY2023Q2 us-gaap Assets
Assets
1014821 usd
CY2022Q4 us-gaap Assets
Assets
1281266 usd
CY2023Q2 ENDV Accrued Interest Related To Notes Payable
AccruedInterestRelatedToNotesPayable
4134397 usd
CY2022Q4 ENDV Accrued Interest Related To Notes Payable
AccruedInterestRelatedToNotesPayable
3542650 usd
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
25585 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
10587 usd
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
5902829 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
17359064 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
23136756 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33381760 usd
CY2023Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
79825 usd
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
79825 usd
CY2023Q2 us-gaap Liabilities
Liabilities
23216581 usd
CY2022Q4 us-gaap Liabilities
Liabilities
33461585 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2500000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2500000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
278802405 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
278802405 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
213227538 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
213227538 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
27880 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
21322 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
43636323 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
42919086 usd
CY2023Q2 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
1570 usd
CY2022Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
1570 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65864419 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-75119183 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-22201760 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-32180319 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1014821 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1281266 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45200 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
650 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
132740 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2932 usd
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
383 usd
us-gaap Cost Of Revenue
CostOfRevenue
3996 usd
us-gaap Cost Of Revenue
CostOfRevenue
1097 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
45200 usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
267 usd
us-gaap Gross Profit
GrossProfit
128744 usd
us-gaap Gross Profit
GrossProfit
1835 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1176509 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
1799016 usd
us-gaap Operating Expenses
OperatingExpenses
1789343 usd
us-gaap Operating Expenses
OperatingExpenses
2286346 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1131309 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1798749 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1660599 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2284511 usd
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3419564 usd
CY2022Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-316606 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
11445466 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1846964 usd
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
103602 usd
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
104760 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
156062 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
43813 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15328 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-178000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-24518 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-178000 usd
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-312869 usd
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-337536 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-622249 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-673678 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3194969 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-727382 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10954761 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2654829 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2063660 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2526131 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
9294162 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4939340 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
2063660 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2526131 usd
us-gaap Net Income Loss
NetIncomeLoss
9294162 usd
us-gaap Net Income Loss
NetIncomeLoss
-4939340 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
276330405 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
134360871 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
263948243 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106696127 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1350743592 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
134360871 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1338361430 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
106696127 shares
us-gaap Net Income Loss
NetIncomeLoss
9294162 usd
us-gaap Net Income Loss
NetIncomeLoss
-4939340 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
323457 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
323456 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
566500 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
107468 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1281900 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
156062 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
43813 usd
ENDV Amortization Of Note Discount And Original Issue Discount
AmortizationOfNoteDiscountAndOriginalIssueDiscount
14627 usd
ENDV Amortization Of Note Discount And Original Issue Discount
AmortizationOfNoteDiscountAndOriginalIssueDiscount
59138 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
11445466 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1846964 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-11974 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2975 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
74827 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
205844 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
600747 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
614540 usd
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
268770 usd
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
318900 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-338996 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-329436 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
146000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
250000 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
7500 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
6500 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
20000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
253000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
371500 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
243500 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
32504 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-85936 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
98 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
85936 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
32602 usd
us-gaap Notes Issued1
NotesIssued1
109000 usd
us-gaap Notes Issued1
NotesIssued1
204000 usd
ENDV Conversion Of Preferred C Stock To Common Stock
ConversionOfPreferredCStockToCommonStock
500 usd
ENDV Issuance Of Common Stock To Settle Debt
IssuanceOfCommonStockToSettleDebt
45000 usd
ENDV Debt Discount From Issuance Of Debt
DebtDiscountFromIssuanceOfDebt
29625 usd
ENDV Debt Discount From Issuance Of Debt
DebtDiscountFromIssuanceOfDebt
33167 usd
ENDV Conversion Of Notes To Common Stock Pursuant To Settlement Agreement
ConversionOfNotesToCommonStockPursuantToSettlementAgreement
159419 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-32180319 usd
CY2023Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
109000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
24870 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
67089 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
172950 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
207000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
7230502 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-24368908 usd
CY2023Q2 ENDV Shares Issued For Conversion Of Deferred Compensation Value
SharesIssuedForConversionOfDeferredCompensationValue
24338 usd
CY2023Q2 ENDV Stock Issued During Period Value Connection With Promissory Notes
StockIssuedDuringPeriodValueConnectionWithPromissoryNotes
11125 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6025 usd
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
16000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
46000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
2063660 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-22201760 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-15774324 usd
CY2022Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
88800 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
46147 usd
CY2022Q1 ENDV Stock Issued During Period Value Connection With Promissory Notes
StockIssuedDuringPeriodValueConnectionWithPromissoryNotes
15750 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2413209 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-18036836 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-18036836 usd
CY2022Q2 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
115200 usd
CY2022Q2 ENDV Stock Issued During Period Value Connection With Promissory Notes
StockIssuedDuringPeriodValueConnectionWithPromissoryNotes
5733 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1281900 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2526131 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2526131 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-19160134 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-19160134 usd
CY2023Q2 us-gaap Cash
Cash
32600 usd
CY2023Q2 ENDV Working Capital Deficiency
WorkingCapitalDeficiency
23100000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-300000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65900000 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
400000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_841_eus-gaap--UseOfEstimates_zJ0AGF4OLVgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zUdyyLaQtW0f">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the assessment of impairment of finite lived intangibles, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
9294162 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4939340 usd
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
-10823217 usd
us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-1529055 usd
us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-4939340 usd
ENDV Weighted Average Number Of Diluted Shares Outstanding Gross
WeightedAverageNumberOfDilutedSharesOutstandingGross
263948243 shares
ENDV Weighted Average Number Of Diluted Shares Outstanding Gross
WeightedAverageNumberOfDilutedSharesOutstandingGross
106696127 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1074413187 shares
ENDV Common Stock And Common Stock Equivalents Used For Diluted Income Per Share
CommonStockAndCommonStockEquivalentsUsedForDilutedIncomePerShare
1338361430 shares
ENDV Common Stock And Common Stock Equivalents Used For Diluted Income Per Share
CommonStockAndCommonStockEquivalentsUsedForDilutedIncomePerShare
106696127 shares
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2063660 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2526131 usd
CY2023Q2 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
-3106695 usd
CY2023Q2 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-1043035 usd
CY2022Q2 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-2526131 usd
CY2023Q2 ENDV Weighted Average Number Of Diluted Shares Outstanding Gross
WeightedAverageNumberOfDilutedSharesOutstandingGross
276330405 shares
CY2022Q2 ENDV Weighted Average Number Of Diluted Shares Outstanding Gross
WeightedAverageNumberOfDilutedSharesOutstandingGross
134360871 shares
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1074413187 shares
CY2023Q2 ENDV Common Stock And Common Stock Equivalents Used For Diluted Income Per Share
CommonStockAndCommonStockEquivalentsUsedForDilutedIncomePerShare
1350743592 shares
CY2022Q2 ENDV Common Stock And Common Stock Equivalents Used For Diluted Income Per Share
CommonStockAndCommonStockEquivalentsUsedForDilutedIncomePerShare
134360871 shares
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45200 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
650 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
132740 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2932 usd
CY2023Q2 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
4500000 usd
CY2022Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
4500000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3558012 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3234556 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
941988 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1265444 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
323456 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
323456 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
646910 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
295078 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
941988 usd
CY2022Q4 us-gaap Notes Payable
NotesPayable
7163832 usd
CY2021Q4 us-gaap Notes Payable
NotesPayable
7256930 usd
ENDV Notes Payable Issued
NotesPayableIssued
150000 usd
CY2022 ENDV Notes Payable Issued
NotesPayableIssued
465000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
27500 usd
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
14000 usd
ENDV Settlements On Note Payable
SettlementsOnNotePayable
-133650 usd
CY2022 ENDV Settlements On Note Payable
SettlementsOnNotePayable
-163826 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
100000 usd
CY2022 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
380272 usd
CY2023Q2 us-gaap Notes Payable
NotesPayable
7052682 usd
CY2022Q4 us-gaap Notes Payable
NotesPayable
7163832 usd
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
25585 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
10587 usd
CY2023Q2 us-gaap Notes And Loans Payable
NotesAndLoansPayable
7027097 usd
CY2022Q4 us-gaap Notes And Loans Payable
NotesAndLoansPayable
7153245 usd
CY2023Q2 ENDV Long Term Debt Past Maturity
LongTermDebtPastMaturity
6837682 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
215000 usd
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
7052682 usd
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
100000 usd
us-gaap Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
9000 usd
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
10900000 shares
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
20000 usd
ENDV Extension Fee Payable
ExtensionFeePayable
2500 usd
ENDV Notes Payable Issued
NotesPayableIssued
150000 usd
CY2023Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1395000 usd
CY2023Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
338403 usd
us-gaap Debt Instrument Description
DebtInstrumentDescription
the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18% reselling the conversion shares
CY2023Q2 ENDV Good Provision Value
GoodProvisionValue
250000 usd
ENDV Certain Fixed Percentage Of Cash Premium
CertainFixedPercentageOfCashPremium
certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% cash premium
CY2022Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
110204 usd
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
93796 usd
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
10200000 shares
CY2022Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1250000 usd
us-gaap Debt Instrument Interest Rate Terms
DebtInstrumentInterestRateTerms
Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% reselling the conversion shares
CY2022Q2 ENDV Good Provision Value
GoodProvisionValue
178000 usd
ENDV Certain Fixed Percentage Of Cash Premium
CertainFixedPercentageOfCashPremium
Certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% premium upon cash redemption by the Company
CY2022Q2 ENDV Prepayment Penalty
PrepaymentPenalty
121000 usd
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
13850000 shares
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
188950 usd
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
62250000 shares
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1281900 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
36000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P2Y6M
CY2023Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
5902829 usd
CY2023Q2 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
5902829 usd

Files In Submission

Name View Source Status
0001493152-23-029706-index-headers.html Edgar Link pending
0001493152-23-029706-index.html Edgar Link pending
0001493152-23-029706.txt Edgar Link pending
0001493152-23-029706-xbrl.zip Edgar Link pending
endv-20230630.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
endv-20230630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
endv-20230630_pre.xml Edgar Link unprocessable
endv-20230630_lab.xml Edgar Link unprocessable
endv-20230630_def.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending